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Abstract
We previously reported that the USP19 deubiquitinating enzyme positively regulates proliferation in fibroblasts by
stabilizing KPC1, a ubiquitin ligase for p27
Kip1. To explore whether this role of USP19 extends to other cellular systems, we
tested the effects of silencing of USP19 in several human prostate and breast models, including carcinoma cell lines.
Depletion of USP19 inhibited proliferation in prostate cancer DU145, PC-3 and 22RV1 cells, which was similar to the pattern
established in fibroblasts in that it was due to decreased progression from G1 to S phase and associated with a stabilization
of the cyclin-dependent kinase inhibitor p27
Kip1. However, in contrast to previous findings in fibroblasts, the stabilization of
p27
Kip1 upon USP19 depletion was not associated with changes in the levels of the KPC1 ligase. USP19 could also regulate
the growth of immortalized MCF10A breast epithelial cells through a similar mechanism. This regulatory pattern was lost,
though, in breast cancer MCF7 and MDA-MB-231 cells and in prostate carcinoma LNCaP cells. Of interest, the transformation
of fibroblasts through overexpression of an oncogenic form of Ras disrupted the USP19-mediated regulation of cell growth
and of levels of p27
Kip1 and KPC1. Thus, the cell context appears determinant for the ability of USP19 to regulate cell
proliferation and p27
Kip1 levels. This may occur through both KPC1 dependent and independent mechanisms. Moreover, a
complete loss of USP19 function on cell growth may arise as a result of oncogenic transformation of cells.
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Introduction
Eukaryotic cell cycle progression is dependent on the precisely
timed activation and inactivation of a series of cyclin-dependent
kinases (CDKs) [1,2]. Activation and inactivation of CDKs occur
by interaction with positive regulatory cyclins and negative
regulatory CDK inhibitors (CKIs) respectively. For example
progression through G1 and into S phase is controlled by the
CDK2 kinase activity and is stimulated by the sequential binding
of cyclins D and E. Premature progression is prevented by the
several CKIs such as p16, p27
Kip1 and p21. One of the best
studied CKIs is p27
Kip1, which intervenes mainly at the G1-S
transition [3]. Upon binding to the cyclin E-CDK2 complex,
p27
Kip1 inhibits CDK2 activity, thereby inhibiting cell cycle
progression and cell proliferation. Silencing of p27
Kip1 results in
enhanced cell proliferation [4]. Consistent with this growth
inhibitory role, p27
Kip1 knockout mice are larger in size than
wild-type littermates. They develop multi-organ hyperplasia and
exhibit increased susceptibility to cancer [5,6,7].
Studies in cancer also support an important role of p27
Kip1 in
regulating cell proliferation. For example, reduced abundance of
p27
Kip1 is often related to high tumor grade and poor prognosis in a
variety of human cancers, including prostate and breast cancers [4].
Seven out of nine multivariate analyses of 1,464 prostate cancer
patients show that reduced nuclear p27
Kip1 is an independent
predictor of decreased time from prostatectomy to disease
recurrence [4]. A systematic review of 18 studies involving 6,216
breast cancer patients showed that reduced levels of p27
Kip1 were an
independent prognostic factor for shortened overall survival and
disease-free survival [8]. Such reduction of p27
Kip1 levels in cancer
cells is often attributed to increased degradation mediated by the
ubiquitin-proteasome pathway [9]. In this process, a cascade of
enzymes (E1: ubiquitin activating enzyme, E2: ubiquitin conjugating
enzyme and E3: ubiquitin-protein ligase) builds up polyubiquitin
chainsonp27
Kip1.Ubiquitinatedp27
Kip1isthendeliveredtothe26S
proteasome for degradation [10]. Multiple E3s have been implicated
in the ubiquitination of p27
Kip1. At the transition from G0 to G1, an
E3 complex, KPC (Kip1 ubiquitination-promoting complex), targets
p27
Kip1 for degradation in the cytoplasm. KPC contains a Ring-
finger catalytic subunit KPC1 that polyubiquitinates p27
Kip1 and an
adaptor protein KPC2 that delivers ubiquitinated p27
Kip1 to the 26S
proteasome for degradation [11,12,13]. At the G1-S transition,
p27
Kip1 becomes a substrate of Skp2, which is an F-box protein that
functions as the substrate recognition component of a SCF-type
Cullin Ring Ligase complex in the nucleus [14,15]. Recently, Pirh2,
a RINGfinger type E3 expressed both inthe nucleus and cytoplasm,
has also been found to target p27
Kip1 for degradation in a panel of
tumor cell lines, including T98G (glioblastoma), MCF7 (breast
carcinoma), Colo320DM (colon carcinoma), and HeLa cells (uterine
cervical carcinoma) [16,17].
Protein ubiquitination is a reversible process. Ubiquitin can be
deconjugated by a family of deubiquitinating enzymes (DUBs)
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15936[18,19]. Although the E3s for polyubiquitination and degradation
of p27
Kip1 have been extensively studied, very little is known about
the role of DUBs in regulating p27
Kip1. We recently identified
USP19 as a DUB that indirectly modulates levels of p27
Kip1 by a
novel mechanism [20]. USP19 deubiquitinates and thereby
stabilizes the KPC1 ligase for p27
Kip1, and so indirectly promotes
degradation of p27
Kip1 and subsequent cell proliferation. This
mechanism was established in rat FR3T3 fibroblasts and
confirmed in mouse embryonic fibroblasts [20]. In the present
investigation, we tested whether the ability of USP19 to regulate
p27
Kip1 and cell proliferation applies more broadly. We found that
the cell context matters with distinctive patterns of USP19
regulation in a panel of human breast and prostate derived cell
lines. We also report that some of the differences may be
attributed, at least in part, to oncogenic cell transformation.
Methods
Reagents
Cell culture media, and Lipofectamine Plus reagent were from
Invitrogen. Propidium iodide, RNase A, cycloheximide and anti-
tubulin antibody were from Sigma. Antibodies to p16, p21 and
Skp2 were from Santa Cruz Biotechnology, and to p27
Kip1, Ras,
caspase 3 from Cell Signaling, to PARP from Roche and to Pirh2
from Calbiochem. Antibodies to KPC1 were a gift from Dr. K.
Nakayama [11]. USP19 antibodies were generated by immunizing
rabbits with a fragment containing the first 129 amino acids of
USP19 [20].
Cell culture
DU145, PC-3, 22RV1, LNCaP clone FGC, MCF10A, MCF 7
and MDA-MB-231 were obtained from the American Type
Culture Collection (ATCC). Parental FR3T3 cells were a gift from
Dr. A. Nepveu. Cells were routinely maintained in culture
medium RPMI1640: DU145, PC-3, 22RV1, LNCaP; MEBM
medium (Lonza): MCF10A; DMEM (high glucose): MCF 7,
MDA-MB-231, and FR3T3, supplemented with 10% fetal bovine
serum (FBS) and antibiotic-antimycotic preparations (Invitrogen).
Puromycin (2 mg/ml) was included for the culture of Ras-V12
transformed FR3T3 and FR3T3-vector cells. Proliferation was
assessed by determining cell number. At the end of the treatment
period, cells were harvested from each well using trypsin, stained
with trypan blue dye and non-stained cells counted on a
hemocytometer. Shown in Figures are mean cell numbers 6 SE
of triplicate samples from a representative experiment. Each
experiment was repeated two to four times.
siRNA transfection
For typical transfection of small interfering RNA (siRNA)
oligonucleotides, 6.5610
5 22RV1 cells, 4610
5 DU145 cells,
4.5610
5 DU145-Vect cells, 4.5610
5 DU145-USP19 cells,
3610
5 PC-3 cells, 7610
5 LNCaP cells, 2.4610
5 HEK293 cells,
5610
5 MCF7, 3.8610
5 MDA-MB-231 and 1.2610
6 MCF10A
cells were seeded into 60 mm plates. SiRNAs were used at 50 nM
for all cell lines with the exception of 55 nM for MCF10A cells.
For LNCaP cells and MDA-MB-231, cell plating and transfection
were performed simultaneously using LNCaP Transfection
Reagent (Altogen Biosystems) and MDA-MB Transfection
Reagent (Altogen Biosystems) respectively. For MCF7, 22RV1,
DU145, DU145-Vect, DU145-USP19 and PC-3 cells, transfection
took place 24 hours after plating using the trans IT-TKO
Transfection Reagent (Mirus) for MCF7, and transfection reagent
Lipofectamine Plus (Invitrogen) for the rest of cell lines. For
MCF10A cells, transfection was performed 48 hours after plating
using X-tremeGENE siRNA Transfection Reagent (Roche). The
transfections were otherwise carried out according to the protocols
of the manufacturers of the indicated transfection reagent. SiRNA
oligonucleotides were purchased from Integrated DNA Technol-
ogies (Coralville, IA) and designed against the following USP19
coding sequences:
Human USP19 siRNA, h1: GGAGGAGATGGCAGTGGCA;
and h6: GGATGGAGATCCTAGGAAA;
Rat USP19 siRNA, #43: GGCGTGACAAGATCAAT-
GACTTG; and #1: AAAGTGCAGACTCACAAGGGT
The sequence of the nonspecific control oligonucleotide was
GUCAGCGUGCAGAUAGAGUUU.
Cell cycle Analysis
Forty-eight hours after USP19 or control siRNA transfection,
DU145 or PC-3 cells were trypsinized, washed and resuspended in
1 ml of ice-cold PBS, subsequently fixed by drop-wise addition of
3 ml ice-cold 70% ethanol and stored in 220uC overnight. FBS
(100 ml) was added to the fixed cells which were then centrifuged,
washed twice in PBS, and incubated in PBS containing 100 mg/ml
RNase A and 10 mg/ml Propidium Iodide for 15 min at 37uC.
Stained cells were counted in FACScan (Becton Dickinson), and
data were analyzed utilizing WinMDI 2.9 software. For each
sample 1610
4 cells were recorded.
BrdU incorporation analysis
Forty-eight hours after USP19 or control siRNA transfection,
DU145 or PC-3 cells were incubated in fresh culture medium with
10 mM BrdU (Roche) for 55 min. Cells were then washed 3 times
with PBS, trypsinized, and resuspended in 0.5 ml PBS. The cells
were stained according to the manufacturer’s protocol, and
counted in a FACS Calibur analyser. Data were analyzed utilizing
WinMDI 2.9 software.
p27
Kip1 Northern blot analysis
RNA was isolated from DU145 cells 48 h after USP19 or
control siRNA transfection using Trizol reagent (Invitrogen)
according to the manufacturer’s protocol. RNA (20 mg) was
electrophoresed on a 1% agarose gel and transferred to a nylon
membrane. The membranes were hybridized with
32P labeled
p27
Kip1 probes, and subjected to autoradiography. Single stranded
cDNA probes were prepared by PCR based amplification using
p27
Kip1 in pCMV (Addgene) as a template and the p27
Kip1 reverse
primer: GAAGAATCGTCGGTTGCAGGTCGCT.
Stable cell lines expressing USP19 or Ras
3610
5 DU145 cells were transduced with retrovirus encoding
pLXSN empty vector (Clontech) or N-terminal 36 Flag-tagged
USP19 in the presence of 8 mg/ml polybrene. The stable clones
wereselected by growingthe cells in culture media containingG418
(400 mg/ml). 6610
5 FR3T3 cells were transduced with retrovirus
carrying pBABE-puro-vector/Ras (G12V) in the presence of 8 mg/
mlpolybrene.Thestablecloneswereselectedbygrowing the cellsin
culture media containing puromycin (2 mg/ml).
Results
Effects of depletion of USP19 on cell proliferation in
prostate cancer cell lines
To investigate the role of USP19 in regulating prostate cancer
cell growth, we depleted this enzyme in several cell lines. We
transfected USP19 siRNA into androgen-independent DU145 and
PC-3 cells as well as androgen-responsive LNCaP and 22RV1 cell
USP19 and Cell Proliferation in Transformed Cells
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USP19 protein levels were suppressed by ,75% in all cell lines.
Depletion of USP19 resulted in a ,50% decrease in cell number
in DU145 and PC-3 cells compared to that of control cells
transfected with a nonspecific siRNA (Fig. 1A). The two
independent USP19 siRNAs tested led to similar reductions in
cell growth, suggesting that this effect in the USP19 depleted
human cells was unlikely to be due to off-target effects. Indeed this
was tested by the stable overexpression in DU145 cells of rat
USP19 that is resistant to targeting by human USP19 siRNA. Our
strategy resulted in a cell line in which USP19 levels did not fall
and in which growth was no longer inhibited upon USP19
depletion (Fig. 1B), thereby confirming the ability of rat USP19 to
reverse the effect of human USP19 siRNA and thus specificity of
action of the siRNA oligonucleotide. The silencing of USP19 was
also growth-inhibitory in 22RV1 cells (Fig. S1A), but not in
LNCaP cells despite a similar extent of silencing of USP19 (Fig.
S1B). These results indicated that USP19 modulates growth in
several but not all prostate cancer cell lines. Moreover, their
differential growth response does not appear strictly due to their
Figure 1. Depletion of USP19 in prostate cancer DU145 and PC-3 cells leads to reduced proliferation. (A) DU145 or PC-3 prostate cancer
cells were transfected with USP19 siRNA oligonucleotides h1 or h6 or nonspecific control siRNA oligonucleotides (CTL). Forty-eight hours after
transfection, cells were harvested and counted. Shown are means 6 SE of triplicate samples. *, P,0.001 compared to CTL. (B) Expressing USP19 in
DU145 cells depleted of endogenous USP19 restores normal proliferation. DU145 cells stably expressing empty vector or rat USP19 that is resistant to
USP19 siRNA oligonucleotide h1 were transfected with h1 or nonspecific (CTL) siRNA oligonucleotide. After 48 h, cells were harvested and counted.
Shown are means 6 SE of triplicate samples. ns, not significant. Cell lysates from DU145-Vect (300 mg of protein) or DU145-USP19 (20 mg of protein)
were analyzed by immunoblotting with the indicated antibodies.
doi:10.1371/journal.pone.0015936.g001
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that USP19 may mediate some of its effects on growth through
androgen receptor dependent pathways.
Depletion of USP19 results in defects in cell cycle
progression
To determine whether the reduction in the number of prostate
cancer cells upon USP19 depletion resulted from a delay in cell
cycle progression, we measured the cell cycle distributions of
DU145 cells transfected with control or USP19 siRNAs. Depletion
of USP19 resulted in a significant increase in the percentage of
cells in G0/G1 phase, which was accompanied by a decrease in S
and G2/M phases compared to that in control cells (Fig. 2A).
Concomitantly, BrdU incorporation, a specific indicator of DNA
synthesis in S phase was reduced ,50% in the cells with USP19
depletion (Fig. 2B). There was no evidence of a sub-G1 peak
(Fig. 2A) and no detectable effects of USP19 depletion on the levels
of apoptotic markers, such as poly (ADP-ribose) polymerase
(PARP) or activated caspase-3 (Fig. 2C). Similar effects on cell
cycle distribution and BrdU incorporation were seen when USP19
was silenced in PC-3 cells (Fig. S2). Therefore, the USP19
modulation of prostate cancer cell growth occurs through a
regulation of cell cycle progression from G0/G1 to S phase and
does not affect the rate of apoptotic cell death.
Depletion of USP19 results in accumulation of p27
Kip1
Since depletion of USP19 delayed G0/G1 to S progression, we
explored possible mechanisms by assessing the steady-state levels
of CKIs that inhibit G0/G1-S transition. USP19 siRNA, but not
control siRNA led to an accumulation of p27
Kip1, but not p16 or
p21 as exemplified in the DU145 model (Fig. 3A). To confirm
that this increased p27
Kip1 was specific to USP19 depletion,
USP19 siRNA was transfected in the stable DU145 cell line
expressing rat USP19. In agreement with above, depletion of
USP19 in DU145 cells expressing empty vector led to an
induction of p27
Kip1. However, in cells overexpressing rat
USP19, the same siRNA treatment was unable to upregulate
p27
Kip1 (Fig. 3B), confirming that the upregulation of p27
Kip1 is a
specific response to USP19 depletion. This increased p27
Kip1
induced by USP19 depletion did not appear to be due to
increased gene transcription, as Northern blot analysis revealed
that p27
Kip1 mRNA levels did not change (Fig. 3C). These data
suggest an involvement of USP19 in regulating the turnover of
p27
Kip1. To test this possibility, the rate of disappearance of
p27
Kip1 was measured in DU145 cells with or without USP19
depletion following inhibition of protein synthesis with cyclohex-
imide. Indeed, in cells transfected with USP19 siRNA p27
Kip1
levels remained relatively stable over time whereas the half-life of
the protein was significantly lower in controls (Fig. 3D), implying
that USP19 modulates the stability of p27
Kip1. To determine
whether the upregulation and stabilization of p27
Kip1 in USP19
depleted DU145 cells was linked to changes in KPC1 expression
as we previously reported [20] or the other E3s, Skp2 and Pirh2,
also responsible for the ubiquitination of p27
Kip1, we measured
the levels of these proteins in response to USP19 depletion.
Unexpectedly, we did not observe any changes in KPC1 (Fig. 3E),
nor in Skp2 and Pirh2 levels (Fig. 3E). These observations
indicate that USP19 can act through a KPC1 and also Skp2 and
Pirh2 independent pathway(s) while still modulating cell growth
and p27
Kip1. Of interest the silencing of USP19 in PC-3 and
22RV1 cells, which also led to an inhibition of their proliferation
resulted in a similar upregulation of p27
Kip1 expression but also
no changes in levels of the three ubiquitin ligases, KPC1, Skp2 or
Pirh2 (Fig. S3). These results suggest that USP19 may lose its
ability to regulate growth such as in the LNCaP cells or still exert
this function through p27
Kip1 as in a variety of other prostate
cancer cell lines but this occurs through a pathway that bypasses
the KPC1 ligase.
Depletion of USP19 results in reduced rates of cell
growth and accumulation of p27
Kip1 in MCF10A breast
epithelial cells but not in MCF7 and MDA-MB-231 breast
carcinoma cells
We next tested the role of USP19 in breast normal cells by
depletion of USP19 in the immortalized MCF10A epithelial cells.
This strategy resulted once more in ,50% inhibition of cell
growth (Fig. 4A) and elevation of p27
Kip1 (Fig. 4B). Again levels of
the E3 ligases, KPC1, Skp2 and Pirh2 did not change (Fig. 4B).
Therefore, the upregulation of p27
Kip1 in USP19 depleted
MCF10A cells appeared to be independent of KPC1, Skp2, or
Pirh2 as was seen in most of the prostate cancer cell lines.
We next asked whether the regulatory role of USP19 in breast
normal epithelial cell growth applied in human breast cancer using
the MCF7 and MDA-MB-231 carcinoma cell lines. Surprisingly,
no changes in cell growth and in levels of p27
Kip1 and the E3
ligases, KPC1 or Skp2 or Pirh2 were observed in either cell line
upon USP19 depletion (Fig. 4C–F). Thus it appears that the ability
of USP19 to regulate cell growth and p27
Kip1 levels is lost in these
breast carcinoma cells, similar to the situation noticed above in the
LNCaP cells.
Role of Ras in the ability of USP19 to regulate cell growth
through p27
Kip1 and KPC1
The striking differences observed between the USP19 growth
regulatory patterns in human breast cells, normal vs carcinoma,
and prostate cancer cell lines as well as rat fibroblasts raised the
question of whether the cell growth response to USP19 depletion
may somehow be associated to oncogenic cell transformation. To
test this possibility and further dissect underlying mechanisms,
FR3T3 cells were transduced stably with a retrovirus expressing an
activated Ras oncogene (Ras-V12) or an empty vector. The effects
upon USP19 depletion were analyzed and compared to cells
transfected with control oligonucleotide. As shown before,
depletion of USP19 in control FR3T3 cells expressing empty
vector resulted in growth inhibition (Fig. 5A) with a corresponding
upregulation of p27
Kip1 and reduction in KPC1 levels (Fig. 5B).
However, in Ras transformed FR3T3 cells, depletion of USP19 no
longer led to any of these changes (Fig. 5A and B). Therefore, the
ability of USP19 to control p27
Kip1 via KPC1 and thereby regulate
cell growth may be abolished when cells are transformed via the
Ras oncogene. Altogether, this strongly suggests that constitutive
activation of the Ras signalling pathway may figure among
mechanisms explaining altered USP19 function and p27
Kip1 levels
in cancer cells.
Discussion
The present investigation explored, for the first time, the ability
of USP19 to regulate growth in diverse cell models, with emphasis
on human prostate and breast cell lines. The rationale was to
determine if the novel mechanism that we established in rodent
fibroblasts applies broadly or is restricted to specific cell systems.
Our findings distinguished three distinct patterns of USP19 action
(Table S1). In the first one, observed in fibroblasts (Fig. 5) and
characterized in detail previously [20], USP19 stabilizes the KPC1
ligase and thereby enhances the ubiquitination of p27
Kip1 in G1
and promotes cell proliferation.
USP19 and Cell Proliferation in Transformed Cells
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cell lines (DU145, PC-3, 22RV1) and in the immortalized breast
normal epithelial cell line, USP19 conserved its ability to positively
regulate cell growth through stimulation of progression through
G1 into S phase and enhanced the rate of degradation of p27
Kip1
(Figs. 1, 2, 4A). However, in contrast to the situation depicted in
fibroblasts, USP19 effects were not mediated through levels of the
KPC1 ligase for p27
Kip1. The underlying mechanism remains
unclear but appears unrelated to levels of Skp2 or Pirh2, other
ligases for p27
Kip1 (Fig. 3E). There is a report that the RING
finger ligase Ro52 binds with Skp2, Cul1, and Skp1 to mediate
ubiquitination of p27
Kip1 in HeLa cells [21]. In this complex,
Ro52 appears to replace the RING finger protein Rbx1that is
typically found in Cul1 based cullin ring ligases and therefore
appears to support ubiquitination of p27
Kip1 only indirectly
through Skp2. Nonetheless, we have measured Ro52 in DU145
cells with and without silencing of USP19 and also did not observe
any differences in levels of this protein (data not shown). It is
possible that USP19 may modulate yet other ligases for p27
Kip1
that have not been uncovered. In addition, we cannot exclude that
p27
Kip1 is also targeted by a non-ubiquitin proteasome dependent
or independent proteolytic mechanism whose activity is promoted
by USP19. Although p27
Kip1 mRNA levels remain unchanged
upon USP19 depletion (Fig. 3C), it remains possible that p27
Kip1
synthesis is regulated also at the level of translation and that
USP19 modulates such translational efficiency of p27
Kip1 mRNA.
All of these possibilities indicate that USP19 has additional
substrates that remain to be identified. Considering that the
number of DUBs encoded in the genome is approximately one
tenth the number of E3s, it is not surprising that a DUB may have
multiple substrates and therefore act on multiple regulatory
pathways in the cell. The net effects of these regulatory
mechanisms, present in varying degrees in different cell types
could lead to divergent outcomes. A recent large scale proteomic
analysis of interacting proteins of deubiquitinating enzymes,
including USP19, has been reported [22]. Many potential
interacting proteins for USP19 were identified, but none appeared
to be putative ubiquitin protein ligases or known modulators of G1
to S progression.
A limitation of this large scale proteomic study was that it was
carried out in human embryonic kidney HEK293 cells. As
demonstrated by our findings, the effects of USP19 and its
mechanisms of action appear to be cell type dependent. Indeed,
silencing of USP19 did not alter growth rates of HEK293 cells
(unpublished data) and so the target of USP19 that mediates its
effects on growth may not be present in these cells. The
identification of USP19 associated molecules and of potentially
novel substrates clearly stem as important questions arising from
our study. However, the search for such proteins, destabilized
and/or more ubiquitinated upon USP19 depletion, needs
precisely to be conducted in a cell specific context.
The third observed pattern was a complete loss of the ability of
USP19 to regulate cell growth and p27
Kip1 levels. This was seen in
the prostate cancer LNCaP model, the breast cancer MCF7 and
MDA-MB-231 models (Fig. 4C–F; Fig S1B), and in fibroblasts
once transformed by the Ras oncogene (Fig. 5). Interestingly,
although USP19 could regulate cell growth in MCF10A breast
epithelial cells, this regulation was lost in breast cancer MCF7 and
MDA-MB-231 cells. This suggested that some aspect of oncogenic
transformation can disrupt USP19 mediated regulation. Indeed,
Figure 2. Depletion of USP19 in DU145 cells results in defects
in cell cycle progression. (A) DU145 cells depleted of USP19 show
accumulation in G1 phase. Forty-eight hours after transfection with
USP19 siRNA oligonucleotide h1 or control oligonucleotide (CTL),
DU145 cells were harvested and subjected to FACS analysis. Shown are
representative profiles and distribution of cells in various phases of the
cycle (expressed as % of total cells 6 SE from three experiments).
*, P,0.001 compared to CTL. (B) DU145 cells depleted of USP19 show
decreased entry into S phase. Forty-eight hours after transfection as in
(A), cells were incubated with BrdU (10 mM) for 55 min and analyzed by
FACS to quantify S phase cells (identified as BrdU positive cells). Shown
are representative profiles and quantitation of percentages of cells that
were BrdU positive or negative. Circles identify the BrdU positive cells in
S phase. #, P,0.005 compared to CTL. (C) Depletion of USP19 did not
affect the levels of poly (ADP-ribose) polymerase (PARP) or activated
caspase-3 in DU145 cells. Cells were transfected as in (A) and harvested
48 h later to analyze protein from lysates by immunoblotting with the
indicated antibodies.
doi:10.1371/journal.pone.0015936.g002
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role of USP19 in fibroblasts can be completely disrupted by
transforming the cells with expression of constitutively active Ras.
This aspect of transformation may also be present in LNCaP cells,
but not in the prostate cancer cell lines that were still inhibitable by
USP19 depletion.
Figure 3. Depletion of USP19 results in accumulation of p27
Kip1 in DU145 cells. (A) p27
Kip1 but not p21 or p16 accumulates in USP19-
depleted DU145 cells. Equal amounts of protein from lysates of cells transfected with control or USP19 siRNA oligonucleotides (as described in Fig. 1A)
were analyzed by immunoblotting with the indicated antibodies. (B) Overexpression of USP19 in DU145 cells prevents USP19 siRNA induced increase
of p27
Kip1. Protein from lysates of cells transfected with control or USP19 siRNA oligonucleotides (as described in Fig. 1B) were analyzed by
immunoblotting with the indicated antibodies. Note that for the USP19 immunoblots, 300 mg of DU145-Vect protein and 20 mg of DU145-USP19
protein were used. (C) Silencing of USP19 does not increase p27
Kip1 levels by increasing mRNA levels. Equal amounts of protein and RNA isolated
from lysates of DU145 cells transfected with USP19 siRNA oligonucleotide h1 or control oligonucleotide (CTL) (as described in Fig. 1A) were analyzed
by Western (top) and Northern (bottom) blots, respectively. (D) Silencing of USP19 stabilizes p27
Kip1. DU145 cells were transfected with USP19 siRNA
oligonucleotide h1 or control oligonucleotide (CTL). Forty-eight hours later, they were incubated with cycloheximide (CHX) to inhibit protein
synthesis. At the indicated times, cells were lysed and proteins were analyzed by immunoblotting with the indicated antibodies. Shown are
representative immunoblots and quantitation of p27
Kip1 levels (means 6 SE) from triplicate samples. *, rate of degradation of p27
Kip1 was significantly
inhibited in USP19 depleted DU145 cells (P,0.05) (two-way analysis of variance). (E) Levels of ubiquitin protein ligases, KPC1, Skp2 and Pirh2 are not
affected upon USP19 depletion in DU145 cells. Equal amounts of protein from lysates (as in Fig. 1A) were analyzed by immunoblotting with the
indicated antibodies. Quantification was performed on triplicate samples and did not reveal any significant differences in the levels of the ligases.
doi:10.1371/journal.pone.0015936.g003
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PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e15936Figure 4. Depletion of USP19 inhibits growth in normal breast epithelial MCF10A but not in breast cancer MCF7 and MDA-MB-231
cells.(A)BreastepithelialMCF10AcellsdepletedofUSP19showreducedproliferation.MCF10Acells weretransfectedwithUSP19siRNAoligonucleotides
h1orh6ornonspecificcontrolsiRNAoligonucleotide(CTL).Forty-eighthoursaftertransfection,cellswereharvestedandcounted.Shownaremeans6SE
of triplicate samples. *, P,0.001 compared to CTL. (B) Depletion of USP19 in MCF10A cells results in a KPC1-independent accumulation of p27
Kip1 in
MCF10A cells. USP19 depleted MCF10A cells from experiment described in Fig. 4A were harvested. Equal amounts of protein from lysates were analyzed
by immunoblotting with the indicated antibodies. (C–F) Depletion of USP19 does not lead to changes in cell growth or p27
Kip1 levels in breast cancer
MCF7 or MDA-MB-231 cells. Forty-eight hours after transfection with USP19 siRNA oligonucleotide h6 or nonspecific control siRNA oligonucleotide (CTL),
cells (C and D) MCF7 and (E and F) MDA-MB-231 were harvested and counted (no significant difference in cell numbers between control and USP19
siRNAs). Equal amounts of protein from lysates were analyzed by immunoblotting with the indicated antibodies.
doi:10.1371/journal.pone.0015936.g004
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PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e15936To date there are very few examples of deubiquitinating
enzymes that have been implicated in tumorigenesis. Mutations in
the CYLD deubiquitinating enzyme leads to familial cylindroma-
tosis [23] and overexpression of USP2 has been reported to
increase prostate cancer cell proliferation through the stabilization
of fatty acid synthase [24]. Very recently, USP17 has been
identified to be highly expressed in primary lung, colon,
esophagus, and cervical cancers and also modulates the stability
of p27
Kip1 in G1 [25]. It appears from expression profiling studies
that USP19 mRNA transcripts do not increase in breast tumors
(Hallett, M and Park M, unpublished data) nor in prostate cancers
[26] compared to their normal adjacent tissues. Along this line,
our attempts to assess levels of USP19 in human prostate cancers
by immunohistochemistry were technically not conclusive, due to
low expression levels in both malignant and normal prostate
tissues. Although we have no evidence yet of increased expression
of USP19 in cancer, it is worth noting that most prostate cancer
cell lines, in particular androgen independent ones, were still
sensitive to loss of USP19. This suggests that pharmacologic
inhibition of USP19 activity may be a useful novel approach for
treatment of prostate cancer, including those tumors that have
become unresponsive to androgen deprivation and often lead to
death.
Collectively, our findings illustrate that depending on the
cellular context, USP19 can regulate growth in a KPC1 dependent
manner or in a KPC1 independent manner, or have no effect on
cell growth. Certain modifications that can occur upon oncogenic
transformation may be responsible for these differences. These
alterations could include changes in the substrates of USP19. To
help identify these substrates, it would be of interest to compare
the pattern of proteins that are destabilized or more ubiquitinated
upon USP19 silencing in cells whose growth is sensitive to USP19
depletion with the pattern of such proteins found in cells whose
growth is insensitive to USP19 depletion.
Supporting Information
Figure S1 Depletion of USP19 results in reduced rates
of cell growth of the androgen- sensitive 22RV1 but not
of LNCaP cell lines. (A) 22RV1 cells depleted of USP19 show
reduced proliferation. Forty-eight hours after transfection with
USP19 siRNA oligonucleotide h1 or nonspecific control siRNA
oligonucleotide (CTL), 22RV1 cells were harvested and counted.
Shown are means 6 SE of triplicate samples. *, P,0.001
compared to CTL. (B) Depletion of USP19 did not change
growth rates of LNCaP cells. Forty-eight hours after transfection
with USP19 siRNA oligonucleotide h1 or h6 or nonspecific
control siRNA oligonucleotide (CTL), LNCaP cells were harvested
and counted. Shown are means 6 standard error of triplicate
samples (no significant difference from results for control siRNA).
(TIF)
Figure S2 Depletion of USP19 in PC-3 cells results in
defects in cell cycle progression. PC-3 cells depleted of
USP19 show accumulation in G1 phase and decreased entry into
S phase. Forty-eight hours after transfection with USP19 siRNA
oligonucleotide h1 or control oligonucleotide (CTL), PC-3 cells
were either harvested and subjected to FACS analysis (top panel)
or incubated with BrdU (10 mM) for 55 min and analyzed by
FACS to quantify S phase cells (identified as BrdU positive cells
and identified by circles) (lower panel). Shown are representative
profiles. *, P,0.001 compared to CTL.
(TIF)
Figure S3 Depletion of USP19 results in accumulation of
p27
Kip1 in PC-3 and 22RV1 cells. Silencing of USP19 in PC-3
and 22RV1 cells increases p27
Kip1 levels, but does not change the
levels of KPC1, Skp2 and Pirh2. Equal amounts of protein from
lysates were analyzed by immunoblotting with the indicated
antibodies.
(TIF)
Table S1 Three distinct patterns of effects of silencing
of USP19 on cell growth, KPC1 ligase and p27
Kip1.
(TIF)
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Figure 5. The ability of depletion of USP19 to regulate cell
growth and p27
Kip1 is lost in FR3T3 fibroblasts transformed by
constitutively active Ras. (A) Rat FR3T3 fibroblasts expressing an
activated Ras oncogene (Ras-V12) or empty vector were transfected
with USP19 siRNA oligonucleotides #1, #43, or nonspecific control
siRNA oligonucleotide (CTL). Forty-eight hours after transfection, cells
were harvested and counted. Shown are means 6 SE of triplicate
samples. *, P,0.001 compared to CTL. (B) USP19 depleted FR3T3-vect
or FR3T3-Ras cells from experiment described in Fig. 5A were harvested.
Equal amounts of protein from lysates were analyzed by immunoblot-
ting with the indicated antibodies.
doi:10.1371/journal.pone.0015936.g005
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